A two-drug combination of Cabometyx, a once-daily pill, and Opdivo, an anti-cancer immunotherapy, improved the survival of previously untreated patients with kidney cancer compared to an older treatment, sunitinib, the companies behind the two drugs said Monday.
The study was eagerly awaited by Cabometyx’s maker, Exelixis, as its investors have fretted that the drug’s sales growth could be slowed by combinations of newer medicines and other immunotherapy treatments.
About the Author Reprints
